PARP Inhibitors for Cancer Therapy | Zendy

Ken Y. Lin | Zendy; W. Lee Kraus | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

PARP Inhibitors for Cancer Therapy

Author(s) -

Ken Y. Lin,

W. Lee Kraus

Publication year - 2017

Publication title -

cell

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 26.304

H-Index - 776

eISSN - 1097-4172

pISSN - 0092-8674

DOI - 10.1016/j.cell.2017.03.034

Subject(s) - olaparib , biology , poly adp ribose polymerase , parp inhibitor , cancer research , germline , somatic cell , dna repair , polymerase , ovarian cancer , synthetic lethality , germline mutation , dna replication , genetics , cancer , mutation , dna , gene

Rucaparib is an inhibitor of nuclear poly (ADP-ribose) polymerases (inhibition of PARP-1 > PARP-2 > PARP-3), following a similar drug, Olaparib. It disrupts DNA repair and replication pathways (and possibly transcription), leading to selective killing of cancer cells with BRCA1/2 mutations. Rucaparib is approved for recurrent ovarian cancers with germline or somatic mutations in BRCA1/2.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research